| 1 |
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.
|
|
|
|
In: Journal of Bone and Mineral Research, vol. 26, no. 5, pp. 984-992 (2011)
|
|
BASE
|
|
Show details
|
|
|
| 2 |
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
|
|
Eastell, R.; Lang, T.; Boonen, S.; Cummings, S.; Delmas, P.D.; Cauley, J.A.; Horowitz, Z.; Kerzberg, E.; Bianchi, G.; Kendler, D.; Leung, P.; Man, Z.; Mesenbrink, P.; Eriksen, E.F.; Black, D.M.; HORIZON Pivotal Fracture, Trial
|
|
In: Osteoporosis International, vol. 21, no. 7, pp. 1277-1285 (2010)
|
|
Abstract:
Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength. INTRODUCTION: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength. METHODS: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated. RESULTS: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001). CONCLUSIONS: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.
|
|
Keyword:
80 and over; Absorptiometry; Aged; Bone Density Conservation Agents/administration & dosage; Bone Density Conservation Agents/therapeutic use; Bone Density/drug effects; Compressive Strength/drug effects; Diphosphonates/administration & dosage; Diphosphonates/therapeutic use; Drug Administration Schedule; Female; Femur Neck/drug effects; Femur Neck/physiopathology; Follow-Up Studies; Hip Joint/drug effects; Hip Joint/physiopathology; Humans; Imidazoles/administration & dosage; Imidazoles/therapeutic use; Lumbar Vertebrae/drug effects; Lumbar Vertebrae/physiopathology; Osteoporosis; Photon/methods; Postmenopausal/drug therapy; Postmenopausal/physiopathology; Tomography; X-Ray Computed/methods
|
|
URL: https://doi.org/10.1007/s00198-009-1077-9
https://serval.unil.ch/notice/serval:BIB_9DE759B0F4B3
|
|
BASE
|
|
Hide details
|
|
|
|
|
